INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
The purpose of this study is to evaluate the efficacy and safety of the study drug, INCB054828, in patients with advanced or surgically unresectable Cholangiocarcinoma.
Surgically Unresectable Cholangiocarcinoma
≥ 18 years of age
Previously treated with at least one prior line of systemic therapy
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.
OHSU Knight Cancer Institute Information line 503-494-1080